Quantcast

Latest asthma Stories

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-13 08:28:16

Two New States Named to the 2014 Asthma and Allergy School Honor Roll During a Record Year for Medication Access, but More Still Needs to Be Done. WASHINGTON, Aug. 13, 2014 /PRNewswire-USNewswire/ -- In just a few weeks, schools will be back in session for the millions of students with asthma and food allergies. So what are schools doing to protect students and teachers with these chronic diseases? Today the Asthma and Allergy Foundation of America (AAFA) revealed its 2014 State Honor...

2014-08-06 12:28:26

Microneedle Patches and Subcutaneous Implants Offer Significant Revenue Potential, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States drug delivery device market will grow at a strong rate to reach a value of over $4.5 billion by 2022 (including device costs only). The future of the drug delivery device market is highly dependent on the pharma industry. Because certain types of drugs are...

2014-08-05 08:33:53

MONROVIA, Calif., Aug. 5, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Desjarlais, Ph.D., senior vice president, research and chief scientific officer, will present at the Wedbush Securities 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 3:40 p.m. EDT in...

2014-08-01 08:26:18

For U.S. Media Only RIDGEFIELD, Conn., Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi(®) Respimat(®) (olodaterol) Inhalation Spray 5 mcg as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STRIVERDI RESPIMAT is not indicated to treat acute...

2014-07-28 13:25:26

University of Manchester Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective. The findings, published in Nature Medicine, show that drugs widely used to treat lung diseases work with the body clock. In the UK pneumonia, which is caused by an infection, affects around 1 in 1000 adults each year and is more serious for babies, young children, the elderly, smokers and those with an underlying health condition....

dust mite allergies
2014-07-26 03:00:43

Richard C. Lewis, University of Iowa Vaccine reduced lung inflammation to allergens in lab and animal tests If you’re allergic to dust mites (and chances are you are), help may be on the way. Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body’s immune response. In animal tests, the nano-sized vaccine package lowered lung inflammation by 83 percent despite repeated exposure to the allergens, according...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-24 08:33:35

MONROVIA, Calif., July 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter financial results after market close on Thursday, July 31, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....


Latest asthma Reference Libraries

Journal of Allergy and Clinical Immunology
2012-05-14 11:51:18

The Journal of Allergy and Clinical Immunology is a medical journal established in 1929 as the Journal of Allergy. It is published by Elsevier. It obtained its current name in 1971. It is the official journal of the American Academy of Allergy, Asthma and Immunology. This journal publishes timely clinical papers, instructive case reports, and detailed examinations of state-of-the-art equipment and techniques to clinical allergists, immunologists, dermatologists, internists, and other...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.